Medical R&D firm Celsion and the Focused Ultrasound Foundation said they are supporting preclinical research designed to explore the use of Celsion's ThermoDox drug candidate in combination with MR-guided, high-intensity focused ultrasound (HIFU) for treating pancreatic cancer.
The studies involving ThermoDox, Celsion's phase III heat-activated liposomal encapsulation of doxorubicin, are being conducted at the University of Washington School of Medicine by director of endoscopic research Dr. Joo Ha Hwang, PhD. Celsion is supporting the research by contributing ThermoDox supplies, while the Focused Ultrasound Foundation is funding a preclinical study.
